- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04115514
Behandling af ARDS med instilleret T3 (ARDS+T3)
Fase II randomiseret, intervention versus ikke-intervention, multicenterundersøgelse af virkningerne af thyreoideahormon (T3) på ekstravaskulært lungevand (EVLW) hos forsøgspersoner med akut respiratorisk distress-syndrom (ARDS)
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
Studieoversigt
Status
Detaljeret beskrivelse
T3 Therapy in ARDS- Phase 2 Randomized, Unblinded, Intervention versus Non- Intervention Trial. Enrollment 68 participants (50 treatment + 18 control). Purpose- To determine the safety and tolerability of T3 delivery into the lungs of ARDS patients, and to measure the effect of T3 on Oxygenation in ARDS patients. Study Drug- Liothyronine Sodium (T3), 50 mcg will be instilled twice daily via a catheter through the ETT into the airway in a total volume of 10 mL (T3+0.9% sodium chloride), over 5 days (10 total doses), or until extubation, whichever comes first.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Minnesota
-
Edina, Minnesota, Forenede Stater, 55435
- M Health Fairview Southdale Hospital
-
Minneapolis, Minnesota, Forenede Stater, 55455
- East Bank Hospital - M Health Fairview University of Minnesota Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Study population is critically ill patients requiring mechanical ventilatory support for ARDS in an intensive care unit.
-
Adults (≥18 years of age).
-
Male or female (non-pregnant).
-
Clinical diagnosis of ARDS (all are required):
- Onset: <= 7 days.
- Chest x-ray: Bilateral Patchy Opacities, Infiltrates.
- Mechanical Vent Support: PEEP or CPAP Support >= 5 cm H2O.
- Pulmonary Edema: Not fully explained by cardiogenic etiology.
- Hypoxia: PaO2/FIO2 Ratio <300, or O2Sat/FIO2 Ratio <315.
-
On mechanical ventilatory support.
-
Capable of giving informed consent directly or from the subject's legally authorized representative (LAR) as determined by the site Principal Investigator and/or Sub- Investigators.
Exclusion Criteria:
Patients with any of the following conditions will be excluded from this trial:
-
Inadequate medical history for determining inclusion/exclusion criteria, as determined by the Principal Investigator and/or Sub- Investigators.
-
Unlikely to complete the protocol with clinic follow-up after discharge, as determined by the Principal Investigator and/or Sub- Investigators or hospice status.
-
Prior history of thyroid cancer or hyperthyroidism, per thorough patient/family interviews, review of past medical history, medication list, laboratory test.
-
Prior history of cardiovascular disease defined as:
- Hypertensive crisis in the past 3 months (systolic >200, or diastolic >120 mmHg),
- Sustained ventricular arrhythmia in the past 3 months (duration >30 seconds)
- Coronary artery disease (documented >=70% occlusion untreated in any coronary vessel), as per the 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization.
- Cardiac-related angina pectoris (>=2 episodes in the past 3 months)
- Myocardial infarction with ischemia on ECG (i.e.,new ST- elevation/depression of >1mm in contiguous leads).
- Peripheral vascular disease (documented >=70% occlusion untreated in any peripheral vessel), as per the 2018 ACC/AHA/SCAI/SIR/SVM Guidelines for Appropriate Use Criteria for Peripheral Artery Intervention.
- Decompensated or symptomatic heart failure (i.e., hospitalized for CHF exacerbation, or a change in CHF medications within two weeks prior)
-
Currently pregnant or breastfeeding.
-
Known allergy to study drug.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment Arm
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation. |
Study Drug Administration:
|
|
Andet: Control arm
Standard of Care |
Standard of Care (SOC) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: baseline
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
baseline
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: 6 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
6 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: 12 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
12 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: 24 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
24 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: 48 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
48 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: 72 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
72 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: 96 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
96 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Tidsramme: 120 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
120 hours post-dose
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
SOC-pressor(er) dosis(er)
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
SOC diuretika dosis(er)
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
Ventilatorfrie dage
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
ICU frie dage
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
Iltfri dage
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
Dødelighed af alle årsager
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
Krav til trakeostomiplacering
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
TSH, Total T3, Fri T3, Fri T4
Tidsramme: baseline og 156 timer efter dosis
|
baseline og 156 timer efter dosis
|
|
|
Gratis T3, Gratis T4
Tidsramme: baseline og 5 dage
|
baseline og 5 dage
|
|
|
Pulmonary events
Tidsramme: baseline and 120 hours post-dose
|
Progressive hemoptysis: bright, red blood in streaks, mixed or clots within sputum on suctioning of greater than 30 mL accumulation anytime following the initial and subsequent intratracheal dosing administrations. |
baseline and 120 hours post-dose
|
|
Cardiovascular event 1
Tidsramme: baseline to 120hours post-dose
|
New sustained ventricular arrhythmia (>30 secs) |
baseline to 120hours post-dose
|
|
Cardiovascular event 2
Tidsramme: baseline to 120hours post-dose
|
New sustained accelerated junctional arrhythmia (rate >80 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 3
Tidsramme: baseline to 120hours post-dose
|
New sustained atrial fibrillation with rapid ventricular response (ventricular rate >160 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 4
Tidsramme: baseline to 120hours post-dose
|
Cardiac arrest (pulseless electrical activity, or asystole). |
baseline to 120hours post-dose
|
|
Cardiovascular event 5
Tidsramme: baseline to 120hours post-dose
|
Hypertensive crisis (systolic pressure of 180 mmHg (or higher), or diastolic pressure of 120 mmHg (or higher) or change in MAP > 20 mmHg with three consecutive measurements over 30 minutes). |
baseline to 120hours post-dose
|
|
SOC pulmonary vasodilator
Tidsramme: baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Supplemental oxygen on discharge
Tidsramme: baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Discharge disposition
Tidsramme: baseline and 5 days
|
home, inpatient rehabilitation, long-term acute care hospital (LTACH) |
baseline and 5 days
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: David H Ingbar, MD, University of Minnesota
- Studieleder: Timothy P Rich, MD, University of Minnesota
- Ledende efterforsker: Ronald A Reikoff, MD, University of Minnesota
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Luftvejsinfektioner
- Infektioner
- Luftvejssygdomme
- Lungesygdomme
- Respirationsforstyrrelser
- Skjoldbruskkirtelsygdomme
- Respiratory Distress Syndrome
- Lungeødem
- Lungebetændelse
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Aminosyrer, peptider og proteiner
- Aminosyrer
- Aminosyrer, aromatisk
- Aminosyrer, cykliske
- Skjoldbruskkirtelhormoner
- Thyroniner
- Thyroxin
- Triiodothyronine
Andre undersøgelses-id-numre
- PACS-2020-23242
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .